{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:41:04Z","timestamp":1790293264881,"version":"4.1.0"},"reference-count":137,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.3892\/ijmm.2016.2620","type":"journal-article","created":{"date-parts":[[2016,5,31]],"date-time":"2016-05-31T08:06:30Z","timestamp":1464681990000},"page":"3-15","source":"Crossref","is-referenced-by-count":366,"title":["FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)"],"prefix":"10.3892","volume":"38","author":[{"given":"MASARU","family":"KATOH","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2016,5,31]]},"reference":[{"key":"key20180107232457_b1-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"key":"key20180107232457_b2-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"key20180107232457_b3-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","article-title":"The ErbB\/HER family of protein-tyrosine kinases and cancer","volume":"79","author":"Roskoski","year":"2014","journal-title":"Pharmacol Res"},{"key":"key20180107232457_b4-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"5474","DOI":"10.1200\/JCO.2005.04.192","article-title":"Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: Pharmacokinetic and clinical results","volume":"23","author":"Rugo","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20180107232457_b5-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"key20180107232457_b6-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1021\/jm400402q","article-title":"Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl) pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials","volume":"56","author":"Marsilje","year":"2013","journal-title":"J Med Chem"},{"key":"key20180107232457_b7-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.1021\/jm2007613","article-title":"Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)","volume":"54","author":"Cui","year":"2011","journal-title":"J Med Chem"},{"key":"key20180107232457_b8-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"638747","DOI":"10.1155\/2014\/638747","article-title":"Antitumor activity of lenvatinib (e7080): An angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models","volume":"2014","author":"Tohyama","year":"2014","journal-title":"J Thyroid Res"},{"key":"key20180107232457_b9-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"key20180107232457_b10-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ijc.25864","article-title":"Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity","volume":"129","author":"Wilhelm","year":"2011","journal-title":"Int J Cancer"},{"key":"key20180107232457_b11-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2006.06.3602","article-title":"Sunitinib: From rational design to clinical efficacy","volume":"25","author":"Chow","year":"2007","journal-title":"J Clin Oncol"},{"key":"key20180107232457_b12-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1200\/JCO.2009.23.6604","article-title":"Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer","volume":"28","author":"Wells","year":"2010","journal-title":"J Clin Oncol"},{"key":"key20180107232457_b13-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cytogfr.2005.01.001","article-title":"Cellular signaling by fibroblast growth factor receptors","volume":"16","author":"Eswarakumar","year":"2005","journal-title":"Cytokine Growth Factor Rev"},{"key":"key20180107232457_b14-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/med.21288","article-title":"FGF receptors: Cancer biology and therapeutics","volume":"34","author":"Katoh","year":"2014","journal-title":"Med Res Rev"},{"key":"key20180107232457_b15-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1042\/CS20140100","article-title":"The ins and outs of fibroblast growth factor receptor signalling","volume":"127","author":"Coleman","year":"2014","journal-title":"Clin Sci (Lond)"},{"key":"key20180107232457_b16-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/wdev.176","article-title":"The fibroblast growth factor signaling pathway","volume":"4","author":"Ornitz","year":"2015","journal-title":"Wiley Interdiscip Rev Dev Biol"},{"key":"key20180107232457_b17-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/jid.2009.97","article-title":"FGFR2 abnormalities underlie a spectrum of bone, skin, and cancer pathologies","volume":"129","author":"Katoh","year":"2009","journal-title":"J Invest Dermatol"},{"key":"key20180107232457_b18-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: From development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"key20180107232457_b19-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1093\/carcin\/bgt254","article-title":"Fibroblast growth factor receptors, developmental corruption and malignant disease","volume":"34","author":"Kelleher","year":"2013","journal-title":"Carcinogenesis"},{"key":"key20180107232457_b20-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10555-015-9579-8","article-title":"Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: Biologic and clinical implications","volume":"34","author":"Helsten","year":"2015","journal-title":"Cancer Metastasis Rev"},{"key":"key20180107232457_b21-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1158\/1078-0432.CCR-11-0699","article-title":"Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer","volume":"18","author":"Brooks","year":"2012","journal-title":"Clin Cancer Res"},{"key":"key20180107232457_b22-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"e105524","DOI":"10.1371\/journal.pone.0105524","article-title":"Prognostic value of FGFR gene amplification in patients with different types of cancer: A systematic review and meta-analysis","volume":"9","author":"Chang","year":"2014","journal-title":"PLoS One"},{"key":"key20180107232457_b23-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"594","DOI":"10.5732\/cjc.013.10178","article-title":"Fusion genes in solid tumors: An emerging target for cancer diagnosis and treatment","volume":"32","author":"Parker","year":"2013","journal-title":"Chin J Cancer"},{"key":"key20180107232457_b24-ijmm-38-01-0003","first-page":"13","article-title":"Fibroblast growth factor receptors: Multifactorial-contributors to tumor initiation and progression","volume":"30","author":"Feng","year":"2015","journal-title":"Histol Histopathol"},{"key":"key20180107232457_b25-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.cytogfr.2013.05.002","article-title":"Small molecule inhibition of fibroblast growth factor receptors in cancer","volume":"24","author":"Liang","year":"2013","journal-title":"Cytokine Growth Factor Rev"},{"key":"key20180107232457_b26-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-015-3301-y","article-title":"Rationale for targeting fibroblast growth factor receptor signaling in breast cancer","volume":"150","author":"Andr\u00e9","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"key20180107232457_b27-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2217\/fon.14.208","article-title":"Dovitinib (CHIR258, TKI258): Structure, development and preclinical and clinical activity","volume":"11","author":"Porta","year":"2015","journal-title":"Future Oncol"},{"key":"key20180107232457_b28-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.tcb.2014.11.003","article-title":"Careless talk costs lives: Fibroblast growth factor receptor signalling and the consequences of pathway malfunction","volume":"25","author":"Carter","year":"2015","journal-title":"Trends Cell Biol"},{"key":"key20180107232457_b29-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.18632\/oncotarget.2987","article-title":"Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer","volume":"6","author":"Chang","year":"2015","journal-title":"Oncotarget"},{"key":"key20180107232457_b30-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1038\/onc.2014.161","article-title":"Ligand-associated ERBB2\/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells","volume":"34","author":"Wang","year":"2015","journal-title":"Oncogene"},{"key":"key20180107232457_b31-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1517\/14728222.2015.1062475","article-title":"The potential of fibroblast growth factor\/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis. Expert","volume":"19","author":"Ronca","year":"2015","journal-title":"Opin Ther Targets"},{"key":"key20180107232457_b32-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"e86470","DOI":"10.1371\/journal.pone.0086470","article-title":"Fibroblast growth factor receptor 3 interacts with and activates TGF\u03b2-activated kinase 1 tyrosine phosphorylation and NF\u03baB signaling in multiple myeloma and bladder cancer","volume":"9","author":"Salazar","year":"2014","journal-title":"PLoS One"},{"key":"key20180107232457_b33-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"key20180107232457_b34-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"62ra93","DOI":"10.1126\/scitranslmed.3001451","article-title":"Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer","volume":"2","author":"Weiss","year":"2010","journal-title":"Sci Transl Med"},{"key":"key20180107232457_b35-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1038\/bjc.2014.229","article-title":"Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer","volume":"110","author":"Cihoric","year":"2014","journal-title":"Br J Cancer"},{"key":"key20180107232457_b36-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.lungcan.2013.10.004","article-title":"High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer","volume":"83","author":"Preusser","year":"2014","journal-title":"Lung Cancer"},{"key":"key20180107232457_b37-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1101\/gr.145144.112","article-title":"The transcriptional landscape and mutational profile of lung adenocarcinoma","volume":"22","author":"Seo","year":"2012","journal-title":"Genome Res"},{"key":"key20180107232457_b38-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1158\/2159-8290.CD-13-0050","article-title":"Identification of targetable FGFR gene fusions in diverse cancers","volume":"3","author":"Wu","year":"2013","journal-title":"Cancer Discov"},{"key":"key20180107232457_b39-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1158\/0008-5472.CAN-14-3771","article-title":"Identification of oncogenic and drug-sensitizing mutations in the extracellular domain of FGFR2","volume":"75","author":"Tanizaki","year":"2015","journal-title":"Cancer Res"},{"key":"key20180107232457_b40-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1038\/485S50a","article-title":"The hard facts","volume":"485","author":"Maxmen","year":"2012","journal-title":"Nature"},{"key":"key20180107232457_b41-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1158\/2159-8290.CD-12-0462","article-title":"The genomic landscape of breast cancer as a therapeutic roadmap","volume":"3","author":"Ellis","year":"2013","journal-title":"Cancer Discov"},{"key":"key20180107232457_b42-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"15578","DOI":"10.18632\/oncotarget.3903","article-title":"Short-term expansion of breast circulating cancer cells predicts response to anti-cancer therapy","volume":"6","author":"Khoo","year":"2015","journal-title":"Oncotarget"},{"key":"key20180107232457_b43-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1126\/science.1253533","article-title":"Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility","volume":"345","author":"Yu","year":"2014","journal-title":"Science"},{"key":"key20180107232457_b44-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1470-2045(13)70611-9","article-title":"Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: A multicentre, prospective trial (SAFIR01\/UNICANCER)","volume":"15","author":"Andr\u00e9","year":"2014","journal-title":"Lancet Oncol"},{"key":"key20180107232457_b45-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1158\/0008-5472.CAN-09-3746","article-title":"FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer","volume":"70","author":"Turner","year":"2010","journal-title":"Cancer Res"},{"key":"key20180107232457_b46-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.ejca.2014.01.029","article-title":"Worldwide trends in gastric cancer mortality 1980\u20132011 with predictions to 2015, and incidence by subtype","volume":"50","author":"Ferro","year":"2014","journal-title":"Eur J Cancer"},{"key":"key20180107232457_b47-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/1479-5876-9-119","article-title":"Deep sequencing of gastric carcinoma reveals somatic mutations relevant to personalized medicine","volume":"9","author":"Holbrook","year":"2011","journal-title":"J Transl Med"},{"key":"key20180107232457_b48-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1136\/gutjnl-2011-301839","article-title":"A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets","volume":"61","author":"Deng","year":"2012","journal-title":"Gut"},{"key":"key20180107232457_b49-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.humpath.2011.12.002","article-title":"Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma","volume":"43","author":"Jung","year":"2012","journal-title":"Hum Pathol"},{"key":"key20180107232457_b50-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/bjc.2013.802","article-title":"FGFR2 amplification has prognostic significance in gastric cancer: Results from a large international multicentre study","volume":"110","author":"Su","year":"2014","journal-title":"Br J Cancer"},{"key":"key20180107232457_b51-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1158\/1078-0432.CCR-12-3898","article-title":"FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547","volume":"19","author":"Xie","year":"2013","journal-title":"Clin Cancer Res"},{"key":"key20180107232457_b52-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"e0134493","DOI":"10.1371\/journal.pone.0134493","article-title":"Patient-derived gastric carcinoma xenograft mouse models faithfully represent human tumor molecular diversity","volume":"10","author":"Zhang","year":"2015","journal-title":"PLoS One"},{"key":"key20180107232457_b53-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1158\/1078-0432.CCR-14-2744","article-title":"Deep sequencing in conjunction with expression and functional analyses reveals activation of FGFR1 in Ewing sarcoma","volume":"21","author":"Agelopoulos","year":"2015","journal-title":"Clin Cancer Res"},{"key":"key20180107232457_b54-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"e60264","DOI":"10.1371\/journal.pone.0060264","article-title":"Activating somatic FGFR2 mutations in breast cancer","volume":"8","author":"Reintjes","year":"2013","journal-title":"PLoS One"},{"key":"key20180107232457_b55-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"e30801","DOI":"10.1371\/journal.pone.0030801","article-title":"FGFR2 point mutations in 466 endometrioid endometrial tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features","volume":"7","author":"Byron","year":"2012","journal-title":"PLoS One"},{"key":"key20180107232457_b56-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/modpathol.2013.135","article-title":"Advanced urothelial carcinoma: Next-generation sequencing reveals diverse genomic alterations and targets of therapy","volume":"27","author":"Ross","year":"2014","journal-title":"Mod Pathol"},{"key":"key20180107232457_b57-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1158\/1541-7786.MCR-08-0021","article-title":"Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma","volume":"7","author":"Gartside","year":"2009","journal-title":"Mol Cancer Res"},{"key":"key20180107232457_b58-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.gene.2012.12.041","article-title":"Comparative functional analysis of two fibroblast growth factor receptor 1 (FGFR1) mutations affecting the same residue (R254W and R254Q) in isolated hypogonadotropic hypogonadism (IHH)","volume":"516","author":"Koika","year":"2013","journal-title":"Gene"},{"key":"key20180107232457_b59-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/gim.2014.166","article-title":"Congenital hypogonadotropic hypogonadism with split hand\/foot malformation: A clinical entity with a high frequency of FGFR1 mutations","volume":"17","author":"Villanueva","year":"2015","journal-title":"Genet Med"},{"key":"key20180107232457_b60-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.humpath.2009.11.003","article-title":"8p11 myeloproliferative syndrome: A review","volume":"41","author":"Jackson","year":"2010","journal-title":"Hum Pathol"},{"key":"key20180107232457_b61-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1309\/AJCPUD6W1JLQQMNA","article-title":"Myeloid and lymphoid neoplasm with abnormalities of FGFR1 presenting with trilineage blasts and RUNX1 rearrangement: A case report and review of literature","volume":"143","author":"Kumar","year":"2015","journal-title":"Am J Clin Pathol"},{"key":"key20180107232457_b62-ijmm-38-01-0003","first-page":"8371","article-title":"Fusion of ETV6 to fibroblast growth factor receptor 3 in peripheral T-cell lymphoma with a t(4;12)(p16;p13) chromosomal translocation","volume":"61","author":"Yagasaki","year":"2001","journal-title":"Cancer Res"},{"key":"key20180107232457_b63-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1182\/blood-2013-03-489823","article-title":"Dysregulated signaling pathways in the development of CNTRL-FGFR1-induced myeloid and lymphoid malignancies associated with FGFR1 in human and mouse models","volume":"122","author":"Ren","year":"2013","journal-title":"Blood"},{"key":"key20180107232457_b64-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/ng.2611","article-title":"St Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project: Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas","volume":"45","author":"Zhang","year":"2013","journal-title":"Nat Genet"},{"key":"key20180107232457_b65-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"6087","DOI":"10.1038\/ncomms7087","article-title":"Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma","volume":"6","author":"Sia","year":"2015","journal-title":"Nat Commun"},{"key":"key20180107232457_b66-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1158\/0008-5472.CAN-11-3034","article-title":"AZD4547: An orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family","volume":"72","author":"Gavine","year":"2012","journal-title":"Cancer Res"},{"key":"key20180107232457_b67-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1158\/1535-7163.MCT-15-0032","article-title":"Antitumor effects and mechanisms of AZD4547 on FGFR2-deregulated endometrial cancer cells","volume":"14","author":"Kwak","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"key20180107232457_b68-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-12-0210","article-title":"FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor","volume":"2","author":"Guagnano","year":"2012","journal-title":"Cancer Discov"},{"key":"key20180107232457_b69-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1158\/2159-8290.CD-14-1029","article-title":"First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway","volume":"5","author":"Hagel","year":"2015","journal-title":"Cancer Discov"},{"key":"key20180107232457_b70-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1158\/1535-7163.MCT-14-0248","article-title":"The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284\/Debio 1347, a novel selective FGFR inhibitor","volume":"13","author":"Nakanishi","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"key20180107232457_b71-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1158\/1078-0432.CCR-04-2129","article-title":"In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models","volume":"11","author":"Lee","year":"2005","journal-title":"Clin Cancer Res"},{"key":"key20180107232457_b72-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"E4869","DOI":"10.1073\/pnas.1403438111","article-title":"Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors","volume":"111","author":"Tan","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180107232457_b73-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1200\/JCO.2014.60.7341","article-title":"Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors","volume":"33","author":"Tabernero","year":"2015","journal-title":"J Clin Oncol"},{"key":"key20180107232457_b74-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1158\/1535-7163.MCT-11-0306","article-title":"A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models","volume":"10","author":"Zhao","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"key20180107232457_b75-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s40264-015-0300-1","article-title":"Update on cardiovascular safety of tyrosine kinase inhibitors: With a special focus on QT interval, left ventricular dysfunction and overall risk\/benefit","volume":"38","author":"Shah","year":"2015","journal-title":"Drug Saf"},{"key":"key20180107232457_b76-ijmm-38-01-0003","first-page":"161","article-title":"Angiogenic factors as potential drug target: Efficacy and limitations of anti-angiogenic therapy","volume":"1846","author":"Gacche","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"key20180107232457_b77-ijmm-38-01-0003","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2015.5932","article-title":"Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: A systematic review and meta-analysis","author":"Douxfils","year":"2016","journal-title":"JAMA Oncol"},{"key":"key20180107232457_b78-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1200\/JCO.2012.46.3653","article-title":"Normalizing tumor microenvironment to treat cancer: Bench to bedside to biomarkers","volume":"31","author":"Jain","year":"2013","journal-title":"J Clin Oncol"},{"key":"key20180107232457_b79-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat Med"},{"key":"key20180107232457_b80-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature12626","article-title":"Influence of tumour micro-environment heterogeneity on therapeutic response","volume":"501","author":"Junttila","year":"2013","journal-title":"Nature"},{"key":"key20180107232457_b81-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/ncb3228","article-title":"Combined CSL and p53 downregulation promotes cancer-associated fibroblast activation","volume":"17","author":"Procopio","year":"2015","journal-title":"Nat Cell Biol"},{"key":"key20180107232457_b82-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1038\/oncsis.2013.4","article-title":"A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop","volume":"2","author":"Ware","year":"2013","journal-title":"Oncogenesis"},{"key":"key20180107232457_b83-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"19647","DOI":"10.18632\/oncotarget.3794","article-title":"FGF23 is elevated in multiple myeloma and increases heparanase expression by tumor cells","volume":"6","author":"Suvannasankha","year":"2015","journal-title":"Oncotarget"},{"key":"key20180107232457_b84-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/nm.2537","article-title":"Tumor angiogenesis: Molecular pathways and therapeutic targets","volume":"17","author":"Weis","year":"2011","journal-title":"Nat Med"},{"key":"key20180107232457_b85-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2217\/fon.11.20","article-title":"Notch regulation of tumor angiogenesis","volume":"7","author":"Bridges","year":"2011","journal-title":"Future Oncol"},{"key":"key20180107232457_b86-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3892\/ijmm.2013.1444","article-title":"Therapeutics targeting angiogenesis: Genetics and epigenetics, extracellular miRNAs and signaling networks (Review)","volume":"32","author":"Katoh","year":"2013","journal-title":"Int J Mol Med"},{"key":"key20180107232457_b87-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ctrv.2011.06.004","article-title":"Targeting angiogenesis in ovarian cancer","volume":"38","author":"Schmitt","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"key20180107232457_b88-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nrc3627","article-title":"VEGF targets the tumour cell","volume":"13","author":"Goel","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"key20180107232457_b89-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"13379","DOI":"10.1073\/pnas.1324235111","article-title":"Endothelial cell FGF signaling is required for injury response but not for vascular homeostasis","volume":"111","author":"Oladipupo","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180107232457_b90-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.canlet.2015.01.012","article-title":"Endostar attenuates melanoma tumor growth via its interruption of b-FGF mediated angiogenesis","volume":"359","author":"Xiao","year":"2015","journal-title":"Cancer Lett"},{"key":"key20180107232457_b91-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10555-014-9538-9","article-title":"Anti-vascular therapies in ovarian cancer: Moving beyond anti-VEGF approaches","volume":"34","author":"Choi","year":"2015","journal-title":"Cancer Metastasis Rev"},{"key":"key20180107232457_b92-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cytogfr.2014.10.013","article-title":"The angiopoietin\/TIE receptor system: Focusing its role for ischemia-reperfusion injury","volume":"26","author":"Hilbert","year":"2015","journal-title":"Cytokine Growth Factor Rev"},{"key":"key20180107232457_b93-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.canlet.2012.08.018","article-title":"Angiopoietins in angiogenesis","volume":"328","author":"Fagiani","year":"2013","journal-title":"Cancer Lett"},{"key":"key20180107232457_b94-ijmm-38-01-0003","first-page":"304","article-title":"Regulation of angiogenesis via Notch signaling in breast cancer and cancer stem cells","volume":"1836","author":"Zhou","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"key20180107232457_b95-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.vph.2014.10.003","article-title":"Notch signal integration in the vasculature during remodeling","volume":"63","author":"Rostama","year":"2014","journal-title":"Vascul Pharmacol"},{"key":"key20180107232457_b96-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1007\/s11427-014-4716-0","article-title":"Notch signaling in blood vessels: From morphogenesis to homeostasis","volume":"57","author":"Zhang","year":"2014","journal-title":"Sci China Life Sci"},{"key":"key20180107232457_b97-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.drudis.2011.08.007","article-title":"Anti-VEGF and beyond: Shaping a new generation of anti-angiogenic therapies for cancer","volume":"16","author":"Bertolini","year":"2011","journal-title":"Drug Discov Today"},{"key":"key20180107232457_b98-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"key20180107232457_b99-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nrc3581","article-title":"History of myeloid-derived suppressor cells","volume":"13","author":"Talmadge","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"key20180107232457_b100-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.coi.2010.01.009","article-title":"Macrophages, innate immunity and cancer: Balance, tolerance, and diversity","volume":"22","author":"Mantovani","year":"2010","journal-title":"Curr Opin Immunol"},{"key":"key20180107232457_b101-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/nri2785","article-title":"FOXP3+ regulatory T cells in the human immune system","volume":"10","author":"Sakaguchi","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"key20180107232457_b102-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/path.3029","article-title":"The chemokine system and cancer","volume":"226","author":"Balkwill","year":"2012","journal-title":"J Pathol"},{"key":"key20180107232457_b103-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1016\/S1470-2045(12)70582-X","article-title":"Cytokine patterns in patients with cancer: A systematic review","author":"Lippitz","year":"2013","journal-title":"Lancet Oncol"},{"key":"key20180107232457_b104-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1146\/annurev-med-051013-052304","article-title":"Regulation of tumor metastasis by myeloid-derived suppressor cells","volume":"66","author":"Condamine","year":"2015","journal-title":"Annu Rev Med"},{"key":"key20180107232457_b105-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.it.2015.02.005","article-title":"Intertwined regulation of angiogenesis and immunity by myeloid cells","volume":"36","author":"Rivera","year":"2015","journal-title":"Trends Immunol"},{"key":"key20180107232457_b106-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/hep.27665","article-title":"CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice","volume":"61","author":"Chen","year":"2015","journal-title":"Hepatology"},{"key":"key20180107232457_b107-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13058-015-0649-1","article-title":"Upregulation of EGFR signaling is correlated with tumor stroma remodeling and tumor recurrence in FGFR1-driven breast cancer","volume":"17","author":"Holdman","year":"2015","journal-title":"Breast Cancer Res"},{"key":"key20180107232457_b108-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1159\/000358640","article-title":"Reductions in myeloid-derived suppressor cells and lung metastases using AZD4547 treatment of a metastatic murine breast tumor model","volume":"33","author":"Liu","year":"2014","journal-title":"Cell Physiol Biochem"},{"key":"key20180107232457_b109-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1182\/blood-2011-09-379214","article-title":"Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling","volume":"119","author":"Hume","year":"2012","journal-title":"Blood"},{"key":"key20180107232457_b110-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"1242974","DOI":"10.1126\/science.1242974","article-title":"Beyond stem cells: Self-renewal of differentiated macrophages","volume":"342","author":"Sieweke","year":"2013","journal-title":"Science"},{"key":"key20180107232457_b111-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.it.2012.08.006","article-title":"Colony stimulating factors and myeloid cell biology in health and disease","volume":"34","author":"Hamilton","year":"2013","journal-title":"Trends Immunol"},{"key":"key20180107232457_b112-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"4742","DOI":"10.1158\/0008-5472.CAN-14-3373","article-title":"Macrophage blockade using CSF1R inhibitors reverses the vascular leakage underlying malignant ascites in late-stage epithelial ovarian cancer","volume":"75","author":"Moughon","year":"2015","journal-title":"Cancer Res"},{"key":"key20180107232457_b113-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8274.CD-10-0028","article-title":"Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy","volume":"1","author":"DeNardo","year":"2011","journal-title":"Cancer Discov"},{"key":"key20180107232457_b114-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1158\/0008-5472.CAN-12-3981","article-title":"CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer","volume":"73","author":"Xu","year":"2013","journal-title":"Cancer Res"},{"key":"key20180107232457_b115-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.ccr.2014.05.016","article-title":"Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy","volume":"25","author":"Ries","year":"2014","journal-title":"Cancer Cell"},{"key":"key20180107232457_b116-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.celrep.2015.03.055","article-title":"Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy","volume":"11","author":"Rivera","year":"2015","journal-title":"Cell Rep"},{"key":"key20180107232457_b117-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrd2792","article-title":"The FGF family: Biology, pathophysiology and therapy","volume":"8","author":"Beenken","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"key20180107232457_b118-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nrd.2015.9","article-title":"Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23","volume":"15","author":"Degirolamo","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"key20180107232457_b119-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1517\/14728222.2014.997711","article-title":"Targeting fibroblast growth factor 19 in liver disease: A potential biomarker and therapeutic target. Expert","volume":"19","author":"Liu","year":"2015","journal-title":"Opin Ther Targets"},{"key":"key20180107232457_b120-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1093\/toxsci\/kfs011","article-title":"Antibody-mediated inhibition of fibroblast growth factor 19 results in increased bile acids synthesis and ileal malabsorption of bile acids in cynomolgus monkeys","volume":"126","author":"Pai","year":"2012","journal-title":"Toxicol Sci"},{"key":"key20180107232457_b121-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"30470","DOI":"10.1074\/jbc.M114.592022","article-title":"Fibroblast growth factor receptor 4 (FGFR4) deficiency improves insulin resistance and glucose metabolism under diet-induced obesity conditions","volume":"289","author":"Ge","year":"2014","journal-title":"J Biol Chem"},{"key":"key20180107232457_b122-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"E426","DOI":"10.1152\/ajpendo.00264.2014","article-title":"FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability","volume":"307","author":"Silswal","year":"2014","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"key20180107232457_b123-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.cmet.2015.09.002","article-title":"Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy","volume":"22","author":"Grabner","year":"2015","journal-title":"Cell Metab"},{"key":"key20180107232457_b124-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1126\/science.1235122","article-title":"Cancer genome landscapes","volume":"339","author":"Vogelstein","year":"2013","journal-title":"Science"},{"key":"key20180107232457_b125-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1158\/1078-0432.CCR-13-3060","article-title":"FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies","volume":"20","author":"Wynes","year":"2014","journal-title":"Clin Cancer Res"},{"key":"key20180107232457_b126-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"e77652","DOI":"10.1371\/journal.pone.0077652","article-title":"Fibroblast growth factor receptors as novel therapeutic targets in SNF5-deleted malignant rhabdoid tumors","volume":"8","author":"W\u00f6hrle","year":"2013","journal-title":"PLoS One"},{"key":"key20180107232457_b127-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"20215","DOI":"10.18632\/oncotarget.4046","article-title":"FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro","volume":"6","author":"K\u00fcnstlinger","year":"2015","journal-title":"Oncotarget"},{"key":"key20180107232457_b128-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1126\/science.1256930","article-title":"Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing","volume":"346","author":"Zhang","year":"2014","journal-title":"Science"},{"key":"key20180107232457_b129-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nature14969","article-title":"The genomic landscape of response to EGFR blockade in colorectal cancer","volume":"526","author":"Bertotti","year":"2015","journal-title":"Nature"},{"key":"key20180107232457_b130-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1126\/science.1254721","article-title":"Patient-derived models of acquired resistance can identify effective drug combinations for cancer","volume":"346","author":"Crystal","year":"2014","journal-title":"Science"},{"key":"key20180107232457_b131-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1038\/onc.2012.319","article-title":"Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance","volume":"32","author":"Chell","year":"2013","journal-title":"Oncogene"},{"key":"key20180107232457_b132-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/PDM.0b013e3182a40fd1","article-title":"Novel mutations in neuroendocrine carcinoma of the breast: Possible therapeutic targets","volume":"23","author":"Ang","year":"2015","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"key20180107232457_b133-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/intimm\/dxm057","article-title":"PD-1 and PD-1 ligands: From discovery to clinical application","volume":"19","author":"Okazaki","year":"2007","journal-title":"Int Immunol"},{"key":"key20180107232457_b134-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"key20180107232457_b135-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: A common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"key20180107232457_b136-ijmm-38-01-0003","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrd4591","article-title":"Combination cancer immunotherapy and new immunomodulatory targets","volume":"14","author":"Mahoney","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"key20180107232457_b137-ijmm-38-01-0003","volume-title":"Development and validation of a scalable next-generation sequencing","author":"Hovelson"}],"container-title":["International Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ijmm.2016.2620\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,7]],"date-time":"2018-01-07T23:53:23Z","timestamp":1515369203000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ijmm.2016.2620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,31]]},"references-count":137,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,5,31]]},"published-print":{"date-parts":[[2016,7]]}},"alternative-id":["10.3892\/ijmm.2016.2620"],"URL":"https:\/\/doi.org\/10.3892\/ijmm.2016.2620","relation":{},"ISSN":["1107-3756","1791-244X"],"issn-type":[{"value":"1107-3756","type":"print"},{"value":"1791-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,31]]}}}